Halozyme Therapeutics

YTD

ALL

Trade Halozyme Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence.

CEO

Helen I. Torley

CEOHelen I. Torley

Employees

423

Employees423

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

423

Employees423

HALO Key Statistics

Market cap

7.72B

Market cap7.72B

Price-Earnings ratio

25.94

Price-Earnings ratio25.94

Dividend yield

—

Dividend yield—

Average volume

1.23M

Average volume1.23M

High today

$68.34

High today$68.34

Low today

$64.45

Low today$64.45

Open price

$65.97

Open price$65.97

Volume

1.52M

Volume1.52M

52 Week high

$82.22

52 Week high$82.22

52 Week low

$47.50

52 Week low$47.50

Stock Snapshot

Halozyme Therapeutics(HALO) stock is priced at $65.54, giving the company a market capitalization of 7.72B. It carries a P/E multiple of 25.94.

On 2026-05-08, Halozyme Therapeutics(HALO) stock moved within a range of $64.45 to $68.34. With shares now at $65.54, the stock is trading +1.7% above its intraday low and -4.1% below the session's peak.

Trading activity shows a volume of 1.52M, compared to an average daily volume of 1.23M.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $82.22 and a low of $47.50.

HALO News

TipRanks 6h

Halozyme Stockholders Back Board, Pay and Auditor Choices

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 10h

Halozyme announces global collaboration and license agreement with GSK

Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has li...

Simply Wall St 4d

The Bull Case For Halozyme Therapeutics Could Change Following Ex-J&J CFO Hire – Learn Why

Halozyme Therapeutics, Inc. recently announced that Darren Snellgrove will become Chief Financial Officer on June 8, 2026, taking charge of the company’s financ...

Analyst ratings

60%

of 10 ratings

Buy

60%

Hold

30%

Sell

10%

More HALO News

Simply Wall St 6d

Halozyme Names New CFO As Valuation Gap And Risks Draw Attention

Halozyme Therapeutics (NasdaqGS:HALO) has appointed Darren Snellgrove as Chief Financial Officer. Snellgrove is described as a seasoned financial executive wit...

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.